Each tablet contains 6.5 mg of Cimicifuga racemosa (L.) Nutt., Rhizoma (blakėžudžių rhizomes) dry extract (product extraction ratio of 4.5 to 8.5: 1), corresponding to 29-55 mg blakėžudžių rhizomes. Extraction solvent - 60% (v / v) ethanol.Therapeutic indications:Light climacteric symptoms such as hot flushes, hot flushes and sweating, the facilitation of women after menopause. Dosage and method of administration :Adult patients after menopause.During the day, you should take one tablet. methodThe tablets should be swallowed or chewed, they can not be sucked. CLIMOFEMIN without a doctor's permission should not be longer than 3 months. Contraindications Hypersensitivity to the active substance or to any of the ingredients CLIMOFEMIN material. Special warnings and precautions for use Patients with a history of liver problems, CLIMOFEMIN should be used with caution (see. 4.8). CLIMOFEMIN should be discontinued immediately and consult a physician if symptoms of possible liver damage signs or symptoms (eg., Fatigue, loss of appetite, jaundice or severe upper abdominal pain, accompanied by nausea and vomiting, or urinating dark-colored urine). If you experience vaginal bleeding or other uncertain or new symptoms, seek medical attention. CLIMOFEMIN without a doctor's permission can not be used with estrogen therapy. Patients who have been treated or are being treated for breast cancer or any other malignant diseases, CLIMOFEMIN not be used. This medicinal product must not be used in patients with rare hereditary problems - problems of galactose intolerance, the Lapp lactase deficiency or glucose-galactose malabsorption. Interaction with other medicinal products and other forms of interaction Data on CLIMOFEMIN interaction. Pregnancy and breast-feeding CLIMOFEMIN during pregnancy and breast-feeding is not recommended. Women of childbearing potential should consider the use of effective contraception before therapy.